EHA 2025 Congress

June 12–15, 2025
Milan, Italy



MPNHub

TOP ABSTRACTS

To help navigate the exciting content being presented at the 30th European Hematology Association (EHA) Congress, the MPN Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MPN.

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at **mpn-hub.com**.
All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

EHA 2025: Top abstracts in MPN

June 12–15, 2025

Oral presentations

Abstract	Title	Presenter	Date and time (CEST)
S220 View	Hematological improvement and other clinical benefits of elritercept as monotherapy and in combination with ruxolitinib in participants with myelofibrosis (MF) from the ongoing phase 2 RESTORE trial	Timothy Devos	Thursday, June 12 17:00–17:15
S221 View	Preliminary data from phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, showed clinical response correlating with cytokine modulation in patients with myelofibrosis	Lindsay Rein	Thursday, June 12 17:15–17:30
S222 View	Ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis and DIPSS low/intermediate-risk myelofibrosis	Harry Gill	Thursday, June 12 17:30–17:45
S223 View	Pelabresib in combination with ruxolitinib for Janus kinase inhibitor-naive patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 study	Alessandro Vannucchi	Thursday, June 12 17:45–18:00
S224 View	SANRECO, an on-going phase1/2 study evaluating divesiran, a novel galnac-conjugated siRNA, in patients with polycythemia vera	Marina Kremyan-skaya	Thursday, June 12 18:00–18:15
S215 View	Clinical characteristics and survival of 312 patients with MPL-mutant essential thrombocythemia: An international European leukemianet collaborative study	Steffen Koschmieder	Friday, June 13 17:00–17:15
S216 View	The revised mutation-adjusted risk score (MARS-r) for predicting overall survival in patients with advanced systemic mastocytosis treated with midostaurin or avapritinib	Johannes Lübke	Friday, June 13 17:15–17:30
S217 View	Neutrophil-to lymphocyte ratio as a surrogate inflammatory biomarker for JAK2V617F suppression and event-free survival in polycythemia vera	Tiziano Barbui	Friday, June 13 17:30–17:45
S218 View	Clinical outcomes in patients with myelofibrosis treated with ruxolitinib and anemia supporting medications	Pankit Vachhani	Friday, June 13 17:45–18:00
S219 View	Genomic profiling for clinical decision making in post-polycythemia vera and post-essential thrombocythemia myelofibrosis	Barbara Mora	Friday, June 13 18:00–18:15
S102 View	Better safety and efficacy with ropeginterferon alfa-2b over anagrelide as second-line treatment of essential thrombocythemia in the topline results of the randomized phase 3 SURPASS-ET trial	Harry Gill	Saturday, June 14 12:15–12:30

Oral presentations (continued)

Abstract	Title	Presenter	Date and time (CEST)
S210 View	Robust mouse model of secondary acute myeloid leukemia: Revealing key role of TP53 mutations and persistent STAT5 activation.	Stefan Constanti-nescu	Sunday, June 15 11:00–11:15
S212 View	INCA035784, a novel, equipotent T cell-redirecting antibody for patients with myeloproliferative neoplasms carrying different types of calreticulin mutations	Beth Psaila	Sunday, June 15 11:30–11:45
LB4002 View	INCA33989 is a novel, first in class, mutant calreticulin-specific monoclonal antibody that demonstrates safety and efficacy in patients with essential thrombocythemia (ET)	John Mascarenhas	Sunday, June 15 09:15–10:45

Posters

Abstract	Title	Presenter	Date and time (CEST)
PF828 View	Survival impact and kinetics of hemoglobin improvement with momelotinib in patients with myelofibrosis and moderate to severe anemia: Post hoc analyses of SIMPLIFY-1 and MOMENTUM	Francesca Palandri	Friday, June 13 18:30–19:30
PF825 View	TYK2 is specifically activated in CALR-mutant myeloproliferative neoplasms and JAK2 expression determines its druggability	Nicolas Chatain	Friday, June 13 18:30–19:30
PS1841 View	Relationship between hemoglobin and quality of life in non-transfusion-dependent patients with myelofibrosis treated with luspatercept	Haifa Kathrin Al-Ali	Saturday, June 14 18:30–19:30
PS1847 View	Deep molecular responses with low-fixed dose of ropeginterferon alfa-2b in a rollover cohort of the LOW-PV trial	Tiziano Barbui	Saturday, June 14 18:30–19:30
PS1794 View	Unraveling the myelofibrotic bone marrow niche: Stromal and immune interactions as potential therapeutic targets	Martina Crysandt	Saturday, June 14 18:30–19:30
PS1818 View	Molecular determinants of resistance to ropeginterferon alfa-2b in PV and ET	Jihyun Song	Saturday, June 14 18:30–19:30
PS1802 View	Germline variants in myeloproliferative neoplasms with early onset or familial history	Elisa Rumi	Saturday, June 14 18:30–19:30
PS1829 View	Impact of dual spleen response and transfusion independence on survival in JAK inhibitor-naive patients with myelofibrosis and anemia treated with momelotinib: A subgroup analysis of SIMPLIFY-1	Francesca Palandri	Saturday, June 14 18:30–19:30

#EHA2025

Follow us on X to keep up to date with the latest from the congress

@MPN_Hub

MPNHub

Brought to you by

SES

This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at **mpn-hub.com**.
All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.